PetMed Express stock gets a new CEO after a 500,000-share plan

PetMed Express stock represents a company valued at USD 30.1 million on September 29, 2026, while a new chief executive takes charge after a difficult operating period. According to StockTitan, Jeffrey Allen Willard became chief executive officer, president and a director effective September 28, 2026.

New CEO takes over September 28

Willard succeeded interim CEO Leslie C.G. Campbell, bringing a leadership change to a retailer whose recent results show falling sales and continuing losses. The appointment also carries a substantial incentive structure, including 250,000 restricted shares and up to 250,000 performance share units, according to StockTitan.

Quarterly loss remains the key risk

For the quarter ended June 30, 2026, PetMed Express reported net sales of USD 41.02 million, down 19.90 percent from USD 51.20 million a year earlier. StockTitan reported a net loss of USD 6.15 million, or USD 0.28 per diluted share, compared with a USD 34.20 million loss, or USD 1.65 per share, in the prior-year quarter.

The comparison is mixed rather than uniformly negative. The smaller net loss reflects the absence of prior-year goodwill and trade name impairment charges, but adjusted EBITDA declined to negative USD 3.40 million from negative USD 2.70 million, while operating cash use was USD 7.70 million versus USD 12.30 million a year earlier.

Revenue decline outweighs the loss improvement

The figures put the new CEO's central challenge in clear numerical terms: lower reported losses have not yet translated into better operating momentum. PetMed Express also reported USD 13.10 million of cash and cash equivalents at June 30, 2026, down from USD 21.40 million at March 31, 2026, according to StockTitan.

Market cap stays near yearly low

PetMed Express had a market capitalization of USD 30.1 million on September 29, 2026. Its 52-week range was USD 1.38 to USD 4.10 on the same date, leaving the valuation profile tied closely to the company's ability to stabilize sales and cash generation.

USD 30.1 million market value

The Nasdaq-listed company operates in specialty retail and sells prescription and non-prescription pet medications, food, supplements and supplies. Its market capitalization stood at USD 30.1 million on September 29, 2026, against a 52-week range of USD 1.38 to USD 4.10.